Patents by Inventor Emily Wright

Emily Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adjuvanted protein vaccines comprising modified full-length spike protein of SARS-CoV-2 composition and methods of use
    Patent number: 12589146
    Abstract: Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non-phospholipid liposome, and wherein the protein is selected from: (i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes; (ii) a modified spike protein sequence of a coronavirus; (iii) a protein sequence from a coronavirus; and (iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections. Also disclose herein are modified spike protein sequence containing a modified full-length SARS-COV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.
    Type: Grant
    Filed: February 22, 2023
    Date of Patent: March 31, 2026
    Assignee: D4 Labs, LLC
    Inventors: David Craig Wright, Michael Bowe, Emily Wright, Peter Pushko
  • DJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USE
    Publication number: 20240277832
    Abstract: Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non-phospholipid liposome, and wherein the protein is selected from: (i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes; (ii) a modified spike protein sequence of a coronavirus; (iii) a protein sequence from a coronavirus; and (iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections. Also disclose herein are modified spike protein sequence containing a modified full-length SARS-COV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.
    Type: Application
    Filed: February 22, 2023
    Publication date: August 22, 2024
    Inventors: David Craig Wright, Michael Bowe, Emily Wright, Peter Pushko
  • Adjuvanted vaccines containing modified S1 Spike protein of SARS-CoV-2 variant C.1.2 for subcutaneous administration and methods of use
    Patent number: 11911461
    Abstract: Disclosed herein are adjuvanted protein vaccines comprising: a SARS-CoV-2 variant C.1.2 modified S1 Spike protein sequence and a non-phospholipid liposome, wherein the protein is encapsulated within the non-phospholipid liposome. The adjuvanted protein vaccines are suitable for subcutaneous administration. Also disclosed herein are modified spike protein sequences containing SARS-CoV-2 variant C.1.2 modified S1 Spike proteins and methods of use of the vaccines and sequences.
    Type: Grant
    Filed: May 5, 2023
    Date of Patent: February 27, 2024
    Assignee: D4 Labs, LLC
    Inventors: David Craig Wright, Michael Bowe, Emily Wright, Peter Pushko